SCHEMBL7253008

SCHEMBL7253008

CN(C)CCn1ncc2ccc(-c3ccsc3)cc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 4/20 0.62
▸ KDR P35968 3/20 0.45
▸ HTR1B P28222 1/20 0.41
▸ BACE1 P56817 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ MAP4K4 O95819 2/20 0.39
▸ TGFBR1 P36897 1/20 0.39
▸ CHEK1 O14757 2/20 0.39
▸ EGFR P00533 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ CHEK2 O96017 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ KMO O15229 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ PIM1 P11309 2/20 0.36
▸ EEF2K O00418 1/20 0.36
▸ DYRK3 O43781 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258088 0.93 HTR1D (0.57) HTR1DKDRHTR1BBACE1HTR7
SCHEMBL7253398 0.88 HTR1D (0.48) HTR1DKDRBACE1HTR7MAP4K4
SCHEMBL7256491 0.87 HTR1D (0.47) HTR1DKDRBACE1HTR7MAP4K4
SCHEMBL7253556 0.83 HTR1D (0.46) HTR1DKDRBACE1HTR7MAP4K4
SCHEMBL7253265 0.83 HTR1D (0.48) HTR1DEGFRHTR2AHTR2CHTR2B
SCHEMBL7256498 0.83 EEF2K (0.46) HTR1DBACE1HTR7MAP4K4CHEK1
SCHEMBL7253520 0.82 HTR1D (0.44) HTR1DBACE1HTR7MAP4K4CHEK1
SCHEMBL7256527 0.82 HTR1D (0.43) HTR1DBACE1HTR7MAP4K4HTR2A
SCHEMBL31351306 0.81 HTR1D (0.44) HTR1DKDRMAP4K4TGFBR1EGFR
SCHEMBL7253012 0.80 HTR1D (0.42) HTR1DBACE1HTR7MAP4K4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6635639-B2 Treatment or diagnosis of central nervous system conditions NPS ALLELIX CORP. (CA) 2003-10-21 — — US claimed
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 — — US claimed
US-6635639-B2 Treatment or diagnosis of central nervous system conditions NPS ALLELIX CORP. (CA) 2003-10-21 — — US disclosed
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 — — US disclosed
US-6380242-B1 FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS NPS ALLELIX CORP. (CA) 2002-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine CNR1, CNR2, KCNH1 HTR1D 128/4885KDR 2144/4885HTR1B 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback